Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2008

Arcalyst(Rilonacept)Kiniksa Pharmaceuticals International, plc logoKNSA

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Kiniksa Pharmaceuticals International, plc

$53.2M

Medicare cost, 2024

Medicare drug plans spent $53.2 million on Arcalyst (rilonacept) in 2024, for 2,303 prescriptions and refills filled by 358 patients. Spending rose 115% from 2023 to 2024. At about $23,096 per prescription it is a high-cost drug. New York accounts for the most spending ($8.9 million, 17% of the total).

Medicare cost, 2024

$53.2M

+114.6% from 2023

Prescriptions

2,303

$23,095.58 per claim

Patients

358

332 prescribers

Total spending, 2024

$53.2M

$148,572.97 per patient

Questions and answers

How much does Medicare spend on Arcalyst?

Medicare prescription drug plans paid $53.2M for Arcalyst in 2024, for 2,303 prescriptions and refills to 358 patients (up 114.6% from 2023). The average cost per claim was $23,095.58.

Which state spends the most on Arcalyst?

New York had the highest Medicare cost for Arcalyst in 2024: $8.9M for 387 claims, followed by California ($7.0M).

Who prescribes Arcalyst the most?

Mary E Heine, nurse practitioner in Cleveland, OH, had the highest Medicare cost for Arcalyst in 2024: 76 claims costing $1.7M.

Who makes Arcalyst?

Arcalyst is made by Kiniksa Pharmaceuticals International, plc (KNSA), listed in the Medicare spending data as Kiniksa Pharmac.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Arcalyst was $53.2M in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Arcalyst, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Mary E Heine Cleveland, OHNurse Practitioner7612$1.7M
Jonathan R Salik Boston, MAInternal Medicine58Under 11$1.6M
Michael S Garshick New York, NYCardiology54Under 11$1.2M
Tracy E Hagerty Pittsfield, MACardiology40Under 11$931K
Allan L Klein Cleveland, OHCardiology29Under 11$659K
Khoa Ngo Albany, NYInternal Medicine27Under 11$589K
Jason C Robin Glenview, ILCardiology25Under 11$574K
Eric J Kozlow Asheboro, NCAllergy/ Immunology22Under 11$496K
Americo A Simonini Los Angeles, CACardiology22Under 11$493K
Anna K Imperato Manhasset, NYRheumatology18Under 11$475K
Lawrence Ukpong Moultrie, GACardiology20Under 11$458K
Jay W Schneider Jacksonville, FLCardiology19Under 11$446K
Joseph Christiana Kingston, NYCardiology19Under 11$426K
Manjusha Anna San Antonio, TXCardiology19Under 11$407K
Russell G Fisher Bedford, TXCardiology12Under 11$381K
Brent A Flickinger Gainesville, GARheumatology16Under 11$375K
Dor Lotan New York, NYAdvanced Heart Failure and Transplant Cardiology18Under 11$370K
Bahram Khazai Miami, FLInterventional Cardiology16Under 11$359K
Georgia K Thomas Baltimore, MDInternal Medicine16Under 11$357K
Sandeep Chandra Tucker, GACardiology16Under 11$355K
Jeffrey F Feiner Laguna Hills, CACardiology15Under 11$351K
Mohammed S Rais Thibodaux, LACardiology15Under 11$349K
Avis E Ware Cincinnati, OHRheumatology15Under 11$346K
Alan H Baik San Francisco, CACardiology16Under 11$345K
Julie A Henry Mason, OHNurse Practitioner13Under 11$342K

Prescriber data by year

YearPrescribersClaimsPatientsCost
20227952587$11.7M
20231731,082173$24.8M
20243322,303358$53.2M

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Kiniksa PharmacKNSA logoKNSA2,303$53.2M

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
2
RxNorm concept IDs
763453, 763457
Application numbers
BLA125249

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube